Selected serotonin subtype receptor agonist to treat sleep apnea

Patent 5356934 Issued on October 18, 1994. Estimated Expiration Date:

June 21, 2013. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Abstract Claims Description Full Text

Patent References

Aryloxyphenylpropylamines in treating depression
Patent #: 4018895
Issued on: 04/19/1977
Inventor: Molloy , et al.

Process for promoting analgesia
Patent #: 4035511
Issued on: 07/12/1977
Inventor: Messing , et al.

Aryloxyphenylpropylamines for obtaining a psychotropic effect
Patent #: 4194009
Issued on: 03/18/1980
Inventor: Molloy , et al.

Arloxyphenylpropylamines
Patent #: 4314081
Issued on: 02/02/1982
Inventor: Molloy , et al.

Analgesic method
Patent #: 4594358
Issued on: 06/10/1986
Inventor: Hynes

Method and compositions for controlling pain, depression and sedation
Patent #: 4698342
Issued on: 10/06/1987
Inventor: Crosby

Pharmaceutical compositions and medical uses of dioxopiperidine derivatives
Patent #: 4738973
Issued on: 04/19/1988
Inventor: Gittos

Method and composition for treating obesity, drug abuse, and narcolepsy
Patent #: 4843071
Issued on: 06/27/1989
Inventor: Hohenwarter

Novel optically active halo-substituted tetrahydrofurans
Patent #: 4918207
Issued on: 04/17/1990
Inventor: Brown

(S)-norfluoxetine in method of inhibiting serotonin uptake Patent #: 5250571
Issued on: 10/05/1993
Inventor: Fuller, et al.

Inventors

Assignee

Eli Lilly and Company

Application

No. 080597 filed on 06/21/1993

US Classes:

514/649Amino nitrogen attached to aryl ring or aryl ring system by an acyclic carbon or acyclic chain

Examiners

Primary: Hollinden, Gary E.

Attorney, Agent or Firm

Jones; Joseph A.

International Class

A61K 031/135

Abstract

The present invention provides a method of employing (R)-fluoxetine to treat sleep Apnea.

Other References

Syvalahti et al., Current Therapeutic Research 25(2), 299 (1979)
Wong, et al., Biochemical Pharmacology, 32(7), 1287 (1983)
Hall, et al., Acta Pharmacol et toxicol., 54, 379 (1984)
Thomas et al., Psychopharmacology, 93, 193 (1987)
Neill et al., Psychopharmacology, 99(2), 196-201 (1989)
Fuller et al., Ser. No. 07/486,478 filed on Feb. 28, 1990
Robertson et al., J. Med Chem., 31 1412 (1988)
Wong et al., Drug Development Research, 6, 397 (1985)
Fuller et al., Pharmacology Biochemistry and Behavior, 24 281 (1986)
Nash et al., Clin. Chem., 28(10), 2100 (1982)
Aronoff et al., Clin. Pharmacol. Ther., 36(1), 138 (1984)
Williams, et al., Sleep Disorders: Diagnosis and Treatment, John Wiley and Sons, (1988) Chapter 4
Hospital Pharmacy, 24, 62-64 (1989)
Edwards, et al., Neuropsychopharmacology, 3(2), 129-136 (1990)
Mueller, et al., Acta Pharmacol. et toxicol., 47, 285-293 (1980)
Garner, et al., Am. Rev. Respir. Dis., 139, 946-950 (1989)
Mendelson, et al., Am. Rev. Respir. Dis., 141, 1527-1530 (1990)
Yoshioka, et al., J. Pharmacol. Exp. Ther., 260(2), 917-924 (1992